IVF and breast cancer: A systematic review and meta-analysis

Human Reproduction Update

Volumn 20, Issue 1, 2014, Pages 106-123

  Sergentanis, Theodoros N ^a   Diamantaras, Andreas Antonios ^a   Perlepe, Christina ^a   Kanavidis, Prodromos ^a   Skalkidou, Alkistis ^b   Petridou, Eleni Th ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Hormones; Infertility; IVF; Meta analysis

Indexed keywords

CLOMIFENE CITRATE; FOLLITROPIN; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE;

ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; CONTROLLED OVARIAN HYPERSTIMULATION; EMBRYO TRANSFER; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLOW UP; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; META ANALYSIS; OVARY HYPERSTIMULATION; PREGNANCY; PRIORITY JOURNAL; PROTECTION; RISK ASSESSMENT; SYSTEMATIC REVIEW;

BREAST CANCER; HORMONES; INFERTILITY; IVF; META-ANALYSIS;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FERTILIZATION IN VITRO; HUMANS; INFERTILITY; INFERTILITY, FEMALE; OVULATION INDUCTION; RISK FACTORS;

EID: 84889642931     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmt034     Document Type: Article

References (213)

1. Abu Hashim H. Clomiphene citrate alternatives for the initial management of polycystic ovary syndrome: an evidence-based approach. Arch Gynecol Obstet 2012; 285:1737-1745.
2. Adami HO, Hunter D, Trichopoulos D. Textbook of Cancer Epidemiology. NY: Oxford University Press, USA, 2008.
3. Akefeldt SO, Finnstrom O, Gavhed D, Henter JI. Langerhans cell histiocytosis in children born 1982-2005 after in vitro fertilization. Acta Paediatr 2012; 101:1151-1155
4. Alder N, Fenty J,Warren F, Sutton AJ, Rushton L, Jones DR, Abrams KR. Meta-analysis of mortality and cancer incidence among workers in the synthetic rubber-producing industry. Am J Epidemiol 2006;164:405-420.
5. Antoni S, Sasco AJ, Dos Santos Silva I, McCormack V. Is mammographic density differentially associated with breast cancer according to receptor status? A meta-analysis. Breast Cancer Res Treat 2013;137:337-347.
6. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ et al. Control of mammary stem cell function by steroid hormone signalling. Nature 2010;465:798-802.
7. Aune D, Chan DS, Vieira AR, Rosenblatt DA, Vieira R, Greenwood DC, Norat T. Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat 2012;134:479-493.
8. Ayhan A, Salman MC,Celik H, Dursun P, Ozyuncu O, Gultekin M. Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers. Acta Obstet Gynecol Scand 2004;83:1104-1111.
9. Basatemur E, Sutcliffe A. Follow-up of children born afterART. Placenta 2008;29(Suppl. B):135-140.
10. Belva F, Roelants M, Painter R, Bonduelle M, Devroey P, De Schepper J. Pubertal development in ICSI children. Hum Reprod 2012;27:1156-1161.
11. Bernstein L, Hanisch R, Sullivan-Halley J, Ross RK. Treatment with human chorionic gonadotropin and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1995; 4:437-440.
12. Blankstein J, Shalev J, SaadonT, Kukia EE, Rabinovici J, Pariente C, Lunenfeld B, SerrDM, Mashiach S. Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril 1987;47:597-602.
13. Blickstein I. Does assisted reproduction technology, per se, increase the risk of preterm birth? BJOG 2006;113 (Suppl. 3):68-71.
14. Bonduelle M, Wennerholm UB, Loft A, Tarlatzis BC, Peters C, Henriet S, Mau C, Victorin-Cederquist A, Van Steirteghem A, Balaska A et al. A multi-centre cohort study of the physical health of 5-year-old children conceived after intracytoplasmic sperm injection, in vitro fertilization and natural conception. Hum Reprod 2005; 20:413-419.
15. Boostanfar R, Mannaerts B, Pang S, Fernandez-Sanchez M, Witjes H, Devroey P. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone. Fertil Steril 2012;97:1351-1358.
16. Borini A, Rebellato E. Focus on breast and ovarian cancer. Placenta 2008;29 (Suppl. B):184-190.
17. Braga C, Negri E, La Vecchia C, Parazzini F, Dal Maso L, Franceschi S. Fertility treatment and risk of breast cancer. Hum Reprod 1996;11:300-303.
18. Brind J, Chinchilli VM, Severs WB, Summy-Long J. Induced abortion as an independent risk factor for breast cancer: a comprehensive review and meta-analysis. J Epidemiol Community Health 1996;50:481-496.
19. Brinton LA. Breast cancer risk after use of fertility drugs: stimulating new controversy. J Natl Cancer Inst 2012;104:962-964.
20. Brinton LA, Schairer C, Hoover RN, Fraumeni JF Jr. Menstrual factors and risk of breast cancer. Cancer Invest 1988;6:245-254.
21. Brinton LA, Scoccia B, Moghissi KS,Westhoff CL, Althuis MD,Mabie JE, Lamb EJ. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod 2004; 19:2005-2013.
22. Brinton LA, Moghissi KS, Scoccia B, Westhoff CL, Lamb EJ. Ovulation induction and cancer risk. Fertil Steril 2005;83:261-274; quiz 525-526.
23. Brinton LA, Trabert B, ShalevV, Lunenfeld E, SellaT, Chodick G. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril 2013;99:1189-1196.
24. Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009;CD002249.
25. Brzezinski A, Peretz T, Mor-Yosef S, Schenker JG. Ovarian stimulation and breast cancer: is there a link? Gynecol Oncol 1994;52:292-295.
26. Bukovic D, Segregur J, Radan M, Sovic T, Hrgovic Z, Simon SA, Fassbender WJ, Fajdic J. Extracorporeal fertilization in the world and in Croatia. Med Arh 2011;65:312-316.
27. Burkman RT, Tang MT, Malone KE, Marchbanks PA, McDonald JA, Folger SG, Norman SA, Strom BL, Bernstein L, Ursin G et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril 2003;79:844-851.
28. Calderon-Margalit R, Friedlander Y, Yanetz R, Deutsch L, Perrin MC, Kleinhaus K, Tiram E, Harlap S, Paltiel O. Preeclampsia and subsequent risk of cancer:update from the Jerusalem Perinatal Study. Am J Obstet Gynecol 2009a;200:63 e61-65.
29. Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC, Manor O, Harlap S, Paltiel O. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol 2009b;169:365-375.
30. Ceelen M, van Weissenbruch MM, Roos JC, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Body composition in children and adolescents born after in vitro fertilization or spontaneous conception. J Clin Endocrinol Metab 2007; 92:3417-3423.
31. Ceelen M, Van Weissen Bruch MM, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Pubertal development in children and adolescents born after IVF and spontaneous conception. Hum Reprod 2008;23:2791-2798.
32. Centers for Disease Control and Prevention. Outline for a national plan for the prevention, detection and management of infertility, 2010. USA. http://www.cdc .gov/art/PDF/NationalActionPlan.pdf (30 June 2012, date last accessed). Cetin I, CozziV, Antonazzo P. Infertility as a cancer risk factor-a review. Placenta 2008; 29:169-177.
33. Chan WS, Dixon ME. The 'ART' of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res 2008; 121:713-726.
34. Check JH, Slovis B. Choosing the right stimulation protocol for in vitro fertilization-embryo transfer in poor, normal, and hyper-responders. Clin Exp Obstet Gynecol 2011;38:313-317.
35. Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One 2012;7:e51446.
36. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, SartoGEet al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-587.
37. Cho H, Aronica SM, Katzenellenbogen BS. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3',5'-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. Endocrinology 1994;134:658-664.
38. Cnattingius S, Eloranta S, Adami HO, Axelsson O, DickmanPW, Hsieh CC, Mucci LA, Trichopoulos D, Lambe M, Johansson AL. Placental weight and risk of invasive epithelial ovarian cancer with an early age of onset. Cancer Epidemiol Biomarkers Prev 2008;17:2344-2349.
39. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012; 13:1141-1151.
40. Connolly M, Gallo F, Hoorens S, Ledger W. Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK. Hum Reprod 2009;24:626-632.
41. Cramer DW, Petterson KS, Barbieri RL, Huhtaniemi IT. Reproductive hormones, cancers, and conditions in relation to a common genetic variant of luteinizing hormone. Hum Reprod 2000;15:2103-2107.
42. D'Angelo A, Brown J, Amso NN. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011; CD002811.
43. Daya S. Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles. Cochrane Database Syst Rev 2000; CD000061.
44. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559-577.
45. DeRoo LA, Cummings P, Mueller BA. Smoking before the first pregnancy and the risk of breast cancer: a meta-analysis. Am J Epidemiol 2011;174:390-402.
46. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
47. Diamond MP, Wentz AC. Ovulation induction with human menopausal gonadotropins. Obstet Gynecol Surv 1986;41:480-490.
48. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, Mashiach S, Modan B. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002;77:324-327.
49. Dorgan JF, Baer DJ, Albert PS, Judd JT, Brown ED, Corle DK, Campbell WS, Hartman TJ, Tejpar AA, Clevidence BA et al. Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst 2001;93:710-715.
50. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002;17:2209-2213.
51. Duckitt K, Templeton A A. Cancer in women with infertility. Curr Opin Obstet Gynecol 1998;10:199-203.
52. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
53. El-Wakeel H, Umpleby HC. Systematic review of fibroadenoma as a risk factor for breast cancer. Breast 2003;12:302-307.
54. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;98:1406-1415.
55. Faupel-Badger JM, Arcaro KF, Balkam JJ, Eliassen AH, Hassiotou F, Lebrilla CB, Michels KB, Palmer JR, Schedin P, Stuebe AM et al. Postpartum remodeling, lactation, and breast cancer risk: summary of a national cancer institute-sponsored workshop. J Natl Cancer Inst 2013;105:166-174.
56. Fei C, Deroo LA, Sandler DP, Weinberg CR. Fertility drugs and young-onset breast cancer: results from the Two Sister Study. J Natl Cancer Inst 2012; 104:1021-1027.
57. Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao Ch V, Tesarik J, Zygmunt M. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril 2005;84:275-284.
58. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662.
59. Friedenreich CM, Cust AE. Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. Br J Sports Med 2008; 42:636-647.
60. Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. Active smoking and breast cancer risk: original cohort data and meta-analysis. J Natl Cancer Inst 2013; 105:515-525.
61. Gauthier E, Paoletti X, Clavel-Chapelon F. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum Reprod 2004;19:2216-2221.
62. Gelbaya TA, Tsoumpou I, Nardo LG. The likelihood of live birth and multiple birth after single versus double embryo transfer at the cleavage stage: a systematic review and meta-analysis. Fertil Steril 2010;94:936-945.
63. George K, Nair R, Tharyan P. Ovulation triggers in anovulatory women undergoing ovulation induction. Cochrane Database Syst Rev 2008;CD006900.
64. Gibreel A, Maheshwari A, Bhattacharya S. Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database Syst Rev 2012;11:CD008528.
65. Grady R, Alavi N, Vale R, Khandwala M, McDonald SD. Elective single embryo transfer and perinatal outcomes: a systematic review and meta-analysis. Fertil Steril 2012; 97:324-331.
66. Hack M, Brish M, Serr DM, Insler V, Lunenfeld B. Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after gonadotropin therapy. JAMA 1970;211:791-797.
67. Hammarberg K, Fisher JR, Wynter KH, Rowe HJ. Breastfeeding after assisted conception: a prospective cohort study. Acta Paediatr 2011;100:529-533.
68. Hansen M, Kurinczuk JJ, de Klerk N, Burton P, Bower C. Assisted reproductive technology and major birth defects in Western Australia. Obstet Gynecol 2012; 120:852-863.
69. Helmerhorst FM, Perquin DA, Donker D, Keirse MJ. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies. BMJ 2004;328:261.
70. Henningsen AK, Pinborg A, Lidegaard O, Vestergaard C, Forman JL, Andersen AN. Perinatal outcome of singleton siblings born after assisted reproductive technology and spontaneous conception: Danish national sibling-cohort study. Fertil Steril 2011;95:959-963.
71. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. www.
72. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
73. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58:295-300.
74. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 2008;93:3295-3298.
75. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 2008;105:5774-5779.
76. Howles CM, Alam V, Tredway D, Homburg R, Warne DW. Factors related to successful ovulation induction in patients with WHO group II anovulatory infertility. Reprod Biomed Online 2010;20:182-190.
77. Hsieh CC, Goldman M, Pavia M, Ekbom A, Petridou E, Adami HO, Trichopoulos D. Breast cancer risk in mothers of multiple births. Int J Cancer 1993;54:81-84.
78. Hugues JN. Comparative use of urinary and recombinant human chorionic gonadotropins in women. Treat Endocrinol 2004;3:371-379.
79. Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 2012;24:134-141.
80. Hvidtjorn D, Schieve L, Schendel D, Jacobsson B, Svaerke C, Thorsen P. Cerebral palsy, autism spectrum disorders, and developmental delay in children born after assisted conception: a systematic review and meta-analysis. Arch Pediatr Adolesc Med 2009; 163:72-83.
81. Jayaprakasan K, Hopkisson J, Campbell B, Johnson I, Thornton J, Raine-Fenning N. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. BJOG 2010; 117:853-862.
82. Jenks S. Sister studies aim to shed light on breast cancer risk. J Natl Cancer Inst 2012; 104:271-272.
83. Jensen RA, Page DL, Dupont WD, Rogers LW. Invasive breast cancer risk in women with sclerosing adenosis. Cancer 1989;64:1977-1983.
84. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev 2007;16:1400-1407.
85. Ji J, Forsti A, Sundquist J, Hemminki K. Risks of breast, endometrial, and ovarian cancers after twin births. Endocr Relat Cancer 2007;14:703-711.
86. Joo BS, Park SH, An BM, Kim KS, Moon SE, Moon HS. Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of in vitro fertilization in a concentration-dependent manner. Fertil Steril 2010;93:442-446.
87. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R. Progesterone induces adult mammary stem cell expansion. Nature 2010;465:803-807.
88. Jourdain O,Avril A, Mauriac L, Quenel N, Bussieres E, RouxD, Lajus C, Dallay D. Breast cancer and in vitro fertilization. About 32 cases. Eur J Obstet Gynecol Reprod Biol 1996; 67:47-52.
89. Källén B, Finnstrom O, Nygren KG, Otterblad Olausson P,Wennerholm UB. In vitro fertilisation in Sweden: obstetric characteristics, maternal morbidity and mortality. BJOG 2005a;112:1529-1535.
90. Källén B, FinnstrwmO, Nygren K, Otterblad Olausson P. In vitro fertilization in Sweden: child morbidity including cancer risk. Fertil Steril 2005b;84:605-610.
91. Källén AJ, Finnstrom OO, Lindam AP, Nilsson EM, Nygren KG, Olausson PM. Cerebral palsy in children born after in vitro fertilization. Is the risk decreasing? Eur J Paediatr Neurol 2010a;14:526-530.
92. Källén B, Finnström O, Lindam A, Nilsson E, Nygren K, Olausson P. Cancer risk in children and young adults conceived by in vitro fertilization. Pediatrics 2010b; 126:270-276.
93. Källén B, Finnstrom O, Lindam A, Nilsson E, Nygren KG, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod 2011; 26:253-258.
94. Kanakas N, Mantzavinos T. Fertility drugs and gynecologic cancer. Ann N Y Acad Sci 2006;1092:265-278.
95. Katz D, Paltiel O, Peretz T, Revel A, Sharon N, Maly B, Michan N, Sklair-Levy M, Allweis T. Beginning IVF treatments after age 30 increases the risk of breast cancer: results of a case-control study. Breast J 2008;14:517-522.
96. Kelly E. Recombinant human follicle-stimulating hormone versus urinary-derived human menopausal gonadotropin for controlled ovarian stimulation: the science and art of assisted reproductive technologies. Fertil Steril 2003;80:1105-1107.
97. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616.
98. Kimberly L, Case A, Cheung AP, Sierra S, Al Asiri S, Carranza-Mamane B, Dwyer C, Graham J, Havelock J, Hemmings R et al. Advanced reproductive age and fertility: no. 269, November 2011. Int J Gynaecol Obstet 2012;117:95-102.
99. Klemetti R, Gissler M, Sevon T, Koivurova S, Ritvanen A, Hemminki E. Children born after assisted fertilization have an increased rate of major congenital anomalies. Fertil Steril 2005;84:1300-1307.
100. Klip H, Burger CW, Kenemans P, van Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes Control 2000; 11:319-344.
101. Knecht KT, Bradford BU, Mason RP, Thurman RG. In vivo formation of a free radical metabolite of ethanol. Mol Pharmacol 1990;38:26-30.
102. Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, Lynch HT, Moller P, FoulkesWD,Randall S et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 2008;19:1111-1119.
103. Kristiansson P, Bjor O, Wramsby H. Tumour incidence in Swedish women who gave birth following IVF treatment. Hum Reprod 2007;22:421-426.
104. Kurinczuk JJ, Hansen M,Bower C. The risk of birth defects in children born after assisted reproductive technologies. Curr Opin Obstet Gynecol 2004;16:201-209.
105. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994;331:5-9.
106. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007;121:856-862.
107. Lehert P, Schertz JC, Ezcurra D. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol 2010;8:112.
108. Lerner-Geva L, Geva E, Lessing JB, Chetrit A, Modan B, Amit A. The possible association between in vitro fertilization treatments and cancer development. Int J Gynecol Cancer 2003;13:23-27.
109. Lerner-Geva L, Keinan-Boker L, Blumstein T, Boyko V, Olmar L, Mashiach S, Rabinovici J, Potashnik G, Lunenfeld E, Schenker JG et al. Infertility, ovulation induction treatments and the incidence of breast cancer-a historical prospective cohort of Israeli women. Breast Cancer Res Treat 2006;100:201-212.
110. Li LL, Zhou J, Qian XJ, Chen YD. Meta-analysis on the possible association between in vitro fertilization and cancer risk. Int J Gynecol Cancer 2013;23:16-24.
111. Liat LG, Jaron R, Liraz O, Tzvia B, Shlomo M, Bruno L. Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up. Gynecol Endocrinol 2012;28:809-814.
112. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-34.
113. Lie RT, Lyngstadaas A, Orstavik KH, Bakketeig LS, Jacobsen G, Tanbo T. Birth defects in children conceived by ICSI compared with children conceived by other IVF-methods; a meta-analysis. Int J Epidemiol 2005;34:696-701.
114. Lim D, Bowdin SC, Tee L, Kirby GA, Blair E, Fryer A, Lam W, Oley C, Cole T, Brueton LA et al. Clinical and molecular genetic features of Beckwith-Wiedemann syndrome associated with assisted reproductive technologies. Hum Reprod 2009; 24:741-747.
115. Litton JK. Breast cancer and fertility. Curr Treat Options Oncol 2012;13:137-145.
116. Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC. Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control 2002;13:299-305.
117. Ludwig M, Diedrich K. Evaluation of an optimal luteal phase support protocol in IVF. Acta Obstet Gynecol Scand 2001;80:452-466.
118. Ludwig M, Doody KJ, Doody KM. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 2003;79:1051-1059.
119. Ludwig M, Katalinic A, Gross S, Sutcliffe A, Varon R, Horsthemke B. Increased prevalence of imprinting defects in patients with Angelman syndrome born to subfertile couples. J Med Genet 2005;42:289-291.
120. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006;8:R43.
121. MacLachlan V, Besanko M, O'Shea F, Wade H, Wood C, Trounson A, Healy DL. A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization. N Engl J Med 1989; 320:1233-1237.
122. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
123. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012; 7:CD004143.
124. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997;6:297-301.
125. Mauvais-Jarvis P. Effects on the breast of drugs used in fertility regulation. Hum Reprod 1987;2:159-162.
126. McDonald SD, HanZ, Mulla S, Murphy KE, Beyene J, Ohlsson A. Preterm birth and low birthweight among in vitro fertilization singletons: a systematic review and meta-analyses. Eur J Obstet Gynecol Reprod Biol 2009;146:138-148.
127. McDonald SD, HanZ, Mulla S, Ohlsson A, Beyene J, Murphy KE. Preterm birth and low birthweight among in vitro fertilization twins: a systematic reviewand meta-analyses. Eur J Obstet Gynecol Reprod Biol 2010;148:105-113.
128. McLaughlin CC, Baptiste MS, Schymura MJ, Nasca PC, Zdeb MS. Maternal and infant birth characteristics and hepatoblastoma. Am J Epidemiol 2006;163: 818-828.
129. McLernon DJ, Harrild K, Bergh C, Davies MJ, de Neubourg D, Dumoulin JC, Gerris J, Kremer JA, Martikainen H, Mol BW et al. Clinical effectiveness of elective single versus double embryo transfer: meta-analysis of individual patient data from randomised trials. BMJ 2010;341:c6945.
130. Medicines andHealthcareProductsRegulatoryAgency.Hormone-replacement therapy: safety update-UK Public Assessment Report. In Hormone-replacement therapy: safety update-UK Public Assessment Report, City, 2007.
131. Messinis IE. Ovulation induction: a mini review. Hum Reprod 2005;20:2688-2697.
132. Misso ML, Teede HJ, Hart R, Wong J, Rombauts L, Melder AM, Norman RJ, Costello MF. Status of clomiphene citrate and metformin for infertility in PCOS. Trends Endocrinol Metab 2012;23:533-543.
133. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1038-1042.
134. Moll AC, Imhof SM, Cruysberg JRM, Schouten-van Meeteren AYN, Boers M, van Leeuwen FE. Incidence of retinoblastoma in children born after in-vitro fertilisation. Lancet 2003;361:309-310.
135. Mullan RJ, Flynn DN, Carlberg B, Tleyjeh IM, Kamath CC, La Bella ML, Erwin PJ, Guyatt GH, Montori VM. Systematic reviewers commonly contact study authors but do so with limited rigor. J Clin Epidemiol 2009;62:138-142.
136. Nakamura Y, Ono M, Yoshida Y, Sugino N, Ueda K, Kato H. Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. Fertil Steril 1997;67:256-260.
137. Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol 2011;8:669-676.
138. National Collaborating Centre for Women's and Children's Health (UK). Fertility: Assessment and Treatment for People with Fertility Problems. London, UK: RCOG Press, 2004.
139. Nechuta S, Paneth N, Velie EM. Pregnancy characteristics and maternal breast cancer risk: a review of the epidemiologic literature. Cancer Causes Control 2010; 21:967-989.
140. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, Buist DS, Kerlikowske K, van RavesteynNT, Trentham-DietzAet al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 2012; 156:635-648.
141. Nyboe Andersen A, Gianaroli L, Nygren KG. Assisted reproductive technology in Europe, 2000. Results generated from European registers by ESHRE. Hum Reprod 2004;19:490-503.
142. Nyboe Andersen A, Goossens V, Bhattacharya S, Ferraretti AP, Kupka MS, de Mouzon J, Nygren KG. Assisted reproductive technology and intrauterine inseminations in Europe, 2005: results generated from European registers by ESHRE: ESHRE. The European IVF Monitoring Programme (EIM), for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod 2009;24:1267-1287.
143. Olson CK, Keppler-Noreuil KM, Romitti PA, Budelier WT, Ryan G, Sparks AE, Van Voorhis BJ. In vitro fertilization is associated with an increase in major birth defects. Fertil Steril 2005;84:1308-1315.
144. Onal H, Ercan O, Adal E, Ersen A, Onal Z. Subclinical hypothyroidism in in vitro fertilization babies. Acta Paediatr 2012;101:e248-e252.
145. Opdahl S, Romundstad PR, Alsaker MD, Vatten LJ. Hypertensive diseases in pregnancy and breast cancer risk. Br J Cancer 2012;107:176-182.
146. Orgeas CC, Sanner K, Hall P, Conner P, Holte J, Nilsson SJ, Sundfeldt K, Persson I, Chia KS, Wedren S et al. Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. Am J Obstet Gynecol 2009;200:72 e71-77.
147. Pappo I, Lerner-Geva L, Halevy A, Olmer L, Friedler S, Raziel A, Schachter M, Ron-El R. The possible association between IVF and breast cancer incidence. Ann Surg Oncol 2008;15:1048-1055.
148. Park SK, Kang D, McGlynn KA, Garcia-Closas M, Kim Y, Yoo KY, Brinton LA. Intrauterine environments and breast cancer risk: meta-analysis and systematic review. Breast Cancer Res 2008;10:R8.
149. Petridou ET, Sergentanis TN, Panagopoulou P, Moschovi M, Polychronopoulou S, Baka M, Pourtsidis A, Athanassiadou F, Kalmanti M, Sidi V et al. In vitro fertilization and risk of childhood leukemia in Greece and Sweden. Pediatr Blood Cancer 2012;58:930-936.
150. Petro-Nustas W, Norton ME, Al-Masarweh I. Risk factors for breast cancer in Jordanian women. J Nurs Scholarsh 2002;34:19-25.
151. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic reviewand meta-analysis. Int J Cancer 1997;71:800-809.
152. Polyzos NP, Messini CI, Papanikolaou EG, Mauri D, Tzioras S, Badawy A, Messinis IE. Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis. Fertil Steril 2010;94:2083-2087.
153. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 1999;71:853-859.
154. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort studyand meta-analysis. Lancet Oncol 2006;7:910-918.
155. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578.
156. Ricci E, Parazzini F, Negri E, Marsico S, La Vecchia C. Fertility drugs and the risk of breast cancer. Hum Reprod 1999;14:1653-1655.
157. Rimm AA, Katayama AC, Katayama KP. Ameta-analysis of the impact of IVF and ICSI on major malformations after adjusting for the effect of subfertility. J Assist Reprod Genet 2011;28:699-705.
158. Ron-El R, Raziel A, Schachter M, Strassburger D, Kasterstein E, Friedler S. Induction of ovulation after gnRH antagonists. Hum Reprod Update 2000;6:318-321.
159. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L, Oelsner G, Serr D. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987;125:780-790.
160. Rossing MA, Daling JR. Complexity of surveillance for cancer risk associated with in-vitro fertilisation. Lancet 1999;354:1573-1574.
161. Rossing MA, Weiss NS. Fertility drugs and breast and ovarian cancer. Lancet 1995; 346:1627-1628.
162. Rossing MA, Daling JR,Weiss NS, Moore DE, Self SG. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol 1996;60:3-7.
163. Rudant J, Amigou A, Orsi L, Althaus T, Leverger G, Baruchel A, Bertrand Y, Nelken B, Plat G, Michel G et al. Fertility treatments, congenital malformations, fetal loss, and childhood acute leukemia: the ESCALE study (SFCE). Pediatr Blood Cancer 2013; 60:301-308.
164. Russo GL, Spinelli GP, TomaoS, Rossi B, Frati L, Panici PB, Vici P, Pisanelli GC, TomaoF. Breast cancer risk after exposure to fertility drugs. Expert Rev Anticancer Ther 2013; 13:149-157.
165. Sakka SD, Malamitsi-Puchner A, Loutradis D, Chrousos GP, Kanaka-Gantenbein C. Euthyroid hyperthyrotropinemia in children born after in vitro fertilization. J Clin Endocrinol Metab 2009;94:1338-1341.
166. Salhab M, Al SarakbiW, Mokbel K. In vitro fertilization and breast cancer risk: a review. Int J Fertil Womens Med 2005;50:259-266.
167. Sazonova A, Kallen K, Thurin-Kjellberg A,Wennerholm UB, Bergh C. Factors affecting obstetric outcome of singletons born after IVF. Hum Reprod 2011;26:2878-2886.
168. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007;7:599-612.
169. Sergentanis TN, Economopoulos KP. Association of two CASP8 polymorphisms with breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010a;120:229-234.
170. Sergentanis TN, Economopoulos KP. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010b;122:459-469.
171. Sergentanis TN, Economopoulos KP. GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010c;121:195-202.
172. Sergentanis TN, Diamantaras AA, Petridou ET. Methodological remarks on the recent meta-analysis examining the possible association between in vitro fertilization and cancer risk. Int J Gynecol Cancer, in press.
173. Shelley J, Venn A, Lumley J. Long-term effects on women of assisted reproduction. Int J Technol Assess Health Care 1999;15:36-51.
174. Siegelmann-DanieliN, Tamir A, Zohar H, Papa MZ, Chetver LL, Gallimidi Z, Stein ME, Kuten A. Breast cancer in women with recent exposure to fertility medications is associated with poor prognostic features. Ann Surg Oncol 2003;10:1031-1038.
175. Silva Idos S, Wark PA, McCormack VA, Mayer D, Overton C, Little V, Nieto J, Hardiman P, Davies M, MacLean AB. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. Br J Cancer 2009;100:1824-1831.
176. Singletary KW, Frey RS, Yan W. Effect of ethanol on proliferation and estrogen receptor-alpha expression in human breast cancer cells. Cancer Lett 2001; 165:131-137.
177. Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou A, Petridou ET. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer-a systematic review and meta-analysis. Hum Reprod Update 2013;19:105-123.
178. StataCorp. Stata Quick Reference and Index. College Station, TX, USA: StataCorp LP, 2009.
179. Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod 2005;20:1511-1515.
180. Stephen EH, Chandra A. Updated projections of infertility in the United States: 1995- 2025. Fertil Steril 1998;70:30-34.
181. Stewart LM, Holman CD, Hart R, Bulsara MK, Preen DB, Finn JC. In vitro fertilization and breast cancer: is there cause for concern? Fertil Steril 2012;98:334-340.
182. Sutcliffe AG, Peters CJ, Bowdin S, Temple K, ReardonW, Wilson L, Clayton-Smith J, Brueton LA, Bannister W, Maher ER. Assisted reproductive therapies and imprinting disorders-a preliminary British survey. Hum Reprod 2006; 21:1009-1011.
183. Suzuki R, Orsini N, Mignone L, Saji S,Wolk A. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis of epidemiological studies. Int J Cancer 2008;122:1832-1841.
184. Talamini R, La Vecchia C, Franceschi S, Colombo F, Decarli A, Grattoni E, Grigoletto E, Tognoni G. Reproductive and hormonal factors and breast cancer in a Northern Italian population. Int J Epidemiol 1985;14:70-74.
185. Tay CC. Use of gonadotrophin-releasing hormone agonists to trigger ovulation. Hum Fertil (Camb) 2002;5:G35-G37; discussion G38-39, G41-38.
186. Taylor VH, Misra M, Mukherjee SD. Is red meat intake a risk factor for breast cancer among premenopausal women? Breast Cancer Res Treat 2009;117:1-8.
187. Terry KL, Willett WC, Rich-Edwards JW, Michels KB. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med 2006;166:2484-2489.
188. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-475.
189. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, Altundag K. Association between common risk factors and molecular subtypes in breast cancer patients. Breast 2013;22:344-350.
190. Twombly R. Too early to determine cancer risk from infertility treatments. J Natl Cancer Inst 2012;104:501-502.
191. Unkila-Kallio L, Leminen A, Tiitnen A, Lehtovirta P, Wahlstrom T, Ylikorkala O. Malignant tumors of the ovary or the breast in association with infertility: a report of thirteen cases. Acta Obstet Gynecol Scand 1997;76:177-181.
192. van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev 2011;CD005354.
193. Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil Steril 2011;95:188-196, 196 e181-183.
194. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995;346:995-1000.
195. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999;354:1586-1590.
196. Venn A, Healy D, McLachlan R. Cancer risks associated with the diagnosis of infertility. Best Pract Res Clin Obstet Gynaecol 2003;17:343-367.
197. Verberg MF, Macklon NS, Nargund G, Frydman R, Devroey P, Broekmans FJ, Fauser BC. Mild ovarian stimulation for IVF. Hum Reprod Update 2009;15: 13-29.
198. Vlahos NF, Economopoulos KP, Fotiou S. Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. Best Pract Res Clin Obstet Gynaecol 2010;24:39-50.
199. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) 2010; 3:696-706.
200. Wang F, Fang Q, Ge Z, Yu N, Xu S, Fan X. Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review. Mol Biol Rep 2012; 39:2109-2118.
201. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality if Nonrandomized Studies in Meta-analyses. Ottawa, Canada: Dept of Epidemiology and Community Medicine, University of Ottawa, 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (30 June 2012, date last accessed).
202. Wohlfahrt J, Melbye M. Maternal risk of breast cancer and birth characteristics of offspring by time since birth. Epidemiology 1999;10:441-444.
203. Wright VC, Schieve LA, Reynolds MA, Jeng G. Assisted reproductive technology surveillance-United States, 2002. MMWR Surveill Summ 2005;54:1-24.
204. Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: a meta-analysis of prospective studies. Breast Cancer Res Treat 2013;137:869-882.
205. Xue F, Michels KB. Intrauterine factors and risk of breast cancer: a systematic reviewand meta-analysis of current evidence. Lancet Oncol 2007;8:1088-1100.
206. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011;103:250-263.
207. Yli-Kuha AN, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Hum Reprod 2012; 27:1149-1155.
208. Youssef MA, Al-Inany HG, Aboulghar M, Mansour R, Abou-Setta AM. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev 2011a;CD003719.
209. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, MochtarMH, Aboulfoutouh I, Khattab SM, vanWely M. Gonadotropin-releasing hormone agonist versusHCGfor oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev 2011b;CD008046.
210. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 2011;12:477-488.
211. Zhu JL, Hvidtjorn D, Basso O, Obel C, Thorsen P, Uldall P, Olsen J. Parental infertility and cerebral palsy in children. Hum Reprod 2010;25:3142-3145.
212. Zhu H, Lei X, Feng J, Wang Y. Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies. Eur J Contracept Reprod Health Care 2012;17:402-414.
213. Zreik TG, Mazloom A, Chen Y, Vannucci M, Pinnix CC, Fulton S, Hadziahmetovic M, Asmar N, Munkarah AR, Ayoub CM et al. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat 2010;124:13-26.